AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials

Fri, 27th Mar 2026 13:44

* Rival treatments had mixed results in the past

* AstraZeneca sees $3-5 billion peak annual ⁠sales for its drug

* Detailed results to be presented at upcoming medical conference

* Shares among biggest gainers on FTSE 100 (Adds quote from interview with company executive in fourth paragraph, updates shares in third paragraph)

March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced flare-ups of chronic obstructive pulmonary disease in two late-stage trials, ⁠sending its shares up as much as 3.8% on Friday on ⁠investor hopes of blockbuster gains if the therapy is approved.

The respiratory treatment met the main goal in the two clinical studies, and reduced the annualised rate of moderate-to-severe COPD flare-ups versus a placebo, the drugmaker said.

Shares in AstraZeneca, Britain's most valuable listed company, were among the biggest percentage gainers on ‌the benchmark FTSE-100 index and were up 3.3% at 1315 GMT after what Jefferies analysts called "a positive surprise".

AstraZeneca's executive vice president for biopharmaceuticals Ruud Dobber told Reuters that the trial data suggested tozorakimab if approved could be used across a relatively broad population of people with the disease, which is commonly caused by long-term smoking. This is because the data showed consistent reductions in exacerbations across the two trials and across patient groups regardless of smoking status, blood eosinophil ‌levels and disease severity, he said.

'HIGHLY CLINICALLY MEANINGFUL' REDUCTION

Tozorakimab showed the "highly clinically meaningful" reduction in the primary trial group of former smokers and in the overall study ‌population, which included current and former smokers with varying levels of lung damage and count of a type of white blood cell.

COPD is a chronic condition that causes restricted airflow and breathing problems. While tobacco smoke is a major trigger, fume inhalation, chemicals and dust in many working environments can also cause onset.

The disease is the fourth-leading cause of death worldwide, according to ‌the World Health Organization.

RIVAL TREATMENTS HAVE HAD MIXED RESULTS AstraZeneca said its drug offers the potential to reduce inflammation and disrupt the cycle of mucus dysfunction that can worsen COPD. Rival treatments from Sanofi-Regeneron and Roche had failed or had ⁠mixed results ⁠in the past.

Tozorakimab and its rivals belong to a class of treatments called monoclonal ‌antibodies, and work by replicating the body's defences and suppressing the action of interleukin-33, a protein involved in inflammation.

AstraZeneca has forecast peak annual sales of $3 billion to $5 billion for tozorakimab. It hopes its more than 20 expected drug launches, along with ‌demand for its cancer drugs, will enable it to achieve its target of $80 billion in annual sales by 2030.

Detailed results from the two studies will be presented at an upcoming medical conference, AstraZeneca said. (Reporting by Pushkala Aripaka and Nithyashree R B in Bengaluru; Editing by Nivedita Bhattacharjee, Barbara Lewis and Louise Heavens)